Nov 2026
Activity and safety of first-line pumitamig plus nab-paclitaxel in triple-negative breast cancer: a single-arm, phase 1b/2 trial.
Jian Zhang, Ye-Hui Shi, Qing-Yuan Zhang et al.
· The Lancet Oncology · 0 citations